within Pharmacolibrary.Drugs.ATC.S;

model S01XA29
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 160 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sepofarsen is an antisense oligonucleotide designed to target and restore c.2991+1655A>G splicing defect in the CEP290 gene. It is investigated for the treatment of Leber congenital amaurosis type 10 (LCA10), a rare genetic retinal degenerative disorder. Sepofarsen is not currently approved by regulatory authorities for general use.</p><h4>Pharmacokinetics</h4><p>No human or animal pharmacokinetic parameter data are available in publications for sepofarsen, including standard references, clinicaltrials reporting, and regulatory documents as of mid-2024. Sepofarsen is administered as an intravitreal injection to the eye, where absorption and distribution are mainly local. Systemic exposure is typically negligible for intravitreal oligonucleotide drugs.</p><h4>References</h4><ol><li><p>Russell, SR, Drack, AV, Cideciyan, AV, Jacobson, SG, Leroy, BP, Van Cauwenbergh, C, Ho, AC, Dumitrescu, AV, Han, IC, Martin, M, Pfeifer, WL, Sohn, EH, Walshire, J, Garafalo, AV, Krishnan, AK, Powers, CA, Sumaroka, A, Roman, AJ, Vanhonsebrouck, E, …, &amp; Girach, A (2022). Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial. <i>Nature medicine</i> 28(5) 1014–1021. DOI:<a href=&quot;https://doi.org/10.1038/s41591-022-01755-w&quot;>10.1038/s41591-022-01755-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35379979/&quot;>https://pubmed.ncbi.nlm.nih.gov/35379979</a></p></li><li><p>Xue, K, &amp; MacLaren, RE (2020). Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. <i>Expert opinion on investigational drugs</i> 29(10) 1163–1170. DOI:<a href=&quot;https://doi.org/10.1080/13543784.2020.1804853&quot;>10.1080/13543784.2020.1804853</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32741234/&quot;>https://pubmed.ncbi.nlm.nih.gov/32741234</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01XA29;
